What Replicor does

Replicor Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Montreal, Quebec, Canada, founded in 2001 with 51–100 employees. The company is developing Nucleic Acid Polymers (NAPs) — a proprietary class of phosphorothioate oligonucleotides whose antiviral activity is independent of nucleotide sequence and instead relies on interaction with exposed hydrophobic protein surfaces common in viral lifecycles. Its lead candidate, REP 2139-Mg, is administered as a once-weekly subcutaneous injection and targets both hepatitis B (HBV) and hepatitis D (HDV), achieving rapid HBsAg reduction in 90% of treated patients and functional cure off-treatment in a majority of cases across Phase II trials.

The product portfolio includes REP 2165-Mg (next-generation NAP with reduced liver accumulation), REP 2139-Ca (calcium formulation from earlier trials), and REP 2055 (proof-of-concept candidate), supported by a granted US patent portfolio authored entirely by CSO Dr. Andrew Vaillant. Replicor has completed four Phase II proof-of-concept trials and published results in The Lancet Gastroenterology & Hepatology, with ongoing collaborations with NIH, University of Adelaide, and INRS – Institut Armand-Frappier. The company currently operates a compassionate access program spanning 16 sites in 8 countries treating 33 HBV/HDV patients with advanced liver disease.

Replicor is pre-revenue and generates no commercial product sales; future revenue is expected to follow regulatory approval and commercialization of REP 2139-Mg via licensing or direct commercialization. Revenue model types are characterized as one-time license, with the company distributing through its compassionate access program as the only current channel. Customers today are not commercial payers but HBV/HDV patient populations seeking functional cure as an alternative to lifelong therapy with current standards of care, including patients with HBV/HDV co-infection (an orphan indication) and those with decompensated cirrhosis.

Name

Replicor

Legal name

Replicor Inc.

Website

http://replicor.com/

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Replicor is a clinical-stage biopharmaceutical company developing Nucleic Acid Polymer (NAP) therapeutics, led by subcutaneous REP 2139-Mg, to achieve functional cure of chronic hepatitis B and hepatitis D in patients with no effective treatment options.

Ownership category

akta.pro rank

Product category

Hepatitis B and D Antiviral Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

• Hepatitis therapeutics
• Nucleic acid polymers
• Antiviral drug development
• HBV HDV treatment
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing NAP-based therapeutics for hepatitis B and D. Revenue will be generated upon regulatory approval and commercialization of REP 2139-Mg.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Replicor is a clinical-stage biopharmaceutical company developing nucleic acid polymer (NAP) based therapeutics, primarily REP 2139-Mg, for the treatment of chronic hepatitis B (HBV) and hepatitis D (HDV) infections. The lead candidate is administered as a once-weekly subcutaneous injection and is being advanced through Phase II clinical trials toward regulatory approval, with a parallel compassionate access program serving patients with advanced liver disease.

Product overview

Replicor is a clinical-stage biopharmaceutical company developing Nucleic Acid Polymer (NAP) based therapies for chronic hepatitis B (HBV) and hepatitis D (HDV) infection. The core product is REP 2139-Mg, a lead NAP candidate administered as a convenient once-weekly subcutaneous injection. The product portfolio includes REP 2165-Mg (next-generation formulation with reduced liver accumulation), REP 2139-Ca (calcium formulation used in early trials), and REP 2055 (first clinical NAP candidate). REP 2139-Mg is the primary candidate progressing through Phase IIA studies following successful compassionate access program data. The NAP technology platform is unique in its mechanism of action - blocking HBsAg release from infected hepatocytes rather than targeting viral nucleotide sequences, making it unaffected by drug resistance. The company has conducted multiple clinical trials including REP 401 (Phase IIb in HBV), REP 301 (Phase II in HBV/HDV co-infection), and compassionate access programs, demonstrating functional cure rates and excellent safety profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• REP 2139-Mg Lead nucleic acid polymer (NAP) candidate for the treatment of chronic hepatitis B (HBV) and hepatitis D (HDV) co-infection; administered as a once-weekly subcutaneous injection and demonstrating rapid HBsAg loss, high cure rates, and a well-tolerated safety profile in clinical trials.
• REP 2165-Mg Next-generation NAP formulation engineered for more rapid elimination from the body with similar antiviral activity and significantly reduced liver accumulation compared to REP 2139; evaluated in combination therapy regimens for chronic HBV.
• REP 2139-Ca Calcium formulation of REP 2139 used in early clinical trials; demonstrated up to 7 log reduction in HBsAg and up to 6 log reduction in HBV DNA or HDV RNA.
• REP 2055 (REP 9AC) First clinical candidate NAP (amphipathic DNA polymer) that demonstrated rapid clearance of HBsAg in serum and allowed patients to regain immunological control over HBV infection; used in proof-of-concept trials.
• NAP Technology Platform Nucleic Acid Polymers (NAPs) technology platform: oligonucleotides whose antiviral activity depends on the sequence-independent activity of phosphorothioate oligonucleotides as biocompatible polymers that interact with exposed hydrophobic surfaces in proteins, blocking release of subviral particles and inhibiting viral replication.
• Compassionate Access Program Closed treatment program providing REP 2139-Mg via subcutaneous injection to patients with very advanced liver disease; demonstrates safety and efficacy across 33 patients in 16 sites in 8 countries.

Quantifiable outcome

• 90% of patients experience rapid HBsAg reduction with >5 log reductions or loss of HBsAg from blood
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• INRS – Institut Armand-FrappiercoreStrategic or Co-development Partner · 6 November 2017Collaborative research partnership to identify mechanisms of subviral particle assembly, supporting the understanding of NAP mechanism of action in treating HBV infection.
• NIH - Liver Diseases BranchcoreStrategic or Co-development Partner · 16 April 2009Collaboration with Dr. Jake Liang's lab at NIH resulted in publication in Gastroenterology demonstrating AP activity against HCV genotypes and effectiveness in preventing HCV infection in vivo.
• University of Adelaide - Dr. Allison Jilbert LabcoreStrategic or Co-development Partner · 1 January 2009Preclinical collaboration demonstrating REP 2055 efficacy in DHBV-infected Pekin ducks - first antiviral to achieve sustained virologic response off-treatment in duck model and show clearance of infection from liver.
• Global Clinical Trial SitescoreOthersClinical trials conducted across 16 sites in 8 countries through compassionate access program, demonstrating REP 2139-Mg safety and efficacy in 33 patients with HBV/HDV infections.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Assembly Biosciences: Clinical-stage biopharma developing HBV core inhibitors and combination therapies for functional cure. Directly comparable to Replicor in target indication and clinical approach, though Assembly uses small-molecule core inhibitors rather than oligonucleotide-based NAPs.
• Arbutus Biopharma: Clinical-stage biopharma developing RNAi-based HBV therapeutics including AB-729. Directly comparable to Replicor as both pursue HBV functional cures using oligonucleotide-based mechanisms, targeting the same patient population and competing for the same regulatory and commercial milestones.
• Vir Biotechnology: Clinical-stage biopharma with a dedicated HBV/HDV program (VIR-2218, VIR-3434) pursuing functional cure. Highly comparable to Replicor in target indication, mechanism class (oligonucleotide/mAb combinations), and clinical stage, with substantially more resources.
• Brii Biosciences: Clinical-stage biopharma focused on HBV functional cure with BRII-179 (therapeutic vaccine) and siRNA candidates. Competes directly with Replicor in HBV curative regimens, particularly in Asia-Pacific markets where HBV prevalence is highest.
• Aligos Therapeutics: Clinical-stage biopharma developing multiple HBV modalities including capsid inhibitors, siRNA, and antisense oligonucleotides. Comparable therapeutic focus on chronic HBV functional cure with similar clinical-stage development.
• Eiger BioPharmaceuticals: Clinical-stage biopharma that developed lonafarnib for HDV (the first approved therapy for HDV). Directly comparable to Replicor as a small clinical-stage company focused specifically on HBV/HDV therapeutics with comparable scale.

Broad incumbents

• Roche: Global biopharma with active HBV cure research programs and established hepatitis franchise (Pegasys). Roche's combination cure strategy and global commercial reach make it a comparable industry participant and potential partner for Replicor's NAP technology.
• GSK: Major biopharma with significant hepatitis franchise including vaccines and antivirals (e.g., Hepsera legacy, current HBV programs). Broad incumbent in hepatitis space with resources to pursue functional cure combinations relevant to Replicor's market.
• Gilead Sciences: Global biopharma and current standard-of-care leader in HBV treatment (Viread/tenofovir, Vemlidy). Gilead is developing next-generation HBV cure regimens and represents both a competitor and potential BD/acquisition partner for Replicor's REP 2139-Mg.

Emerging players

• Altimmune: Clinical-stage biopharma developing HepTcell, an immunotherapeutic for chronic HBV. Comparable therapeutic focus on HBV functional cure via immune restoration, similar clinical stage, and similar small-cap profile to Replicor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/replicorinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Replicor